| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$4,279 |
Final Director's Interest Notice - N Salmon
|
18 Feb 2026 2:27PM |
$32.510 |
$29.750 |
fallen by
8.49%
|
|
| AuMEGA Metals Ltd (AAM) ORDINARY FULLY PAID |
Materials |
$34 |
Reinstatement to Quotation
|
18 Feb 2026 2:27PM |
$0.039 |
$0.038 |
fallen by
2.56%
|
|
AAM - Price-sensitive ASX Announcement
Full Release
Key Points
- Suspension of AuMEGA Metals Ltd (AAM) lifted.
- Reinstatement follows finalisation of capital raising agreements.
- Trading activities to resume on the ASX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AuMEGA Metals Ltd (AAM) ORDINARY FULLY PAID |
Materials |
$34 |
Proposed issue of securities - AAM
|
18 Feb 2026 2:27PM |
$0.039 |
$0.038 |
fallen by
2.56%
|
|
| AuMEGA Metals Ltd (AAM) ORDINARY FULLY PAID |
Materials |
$34 |
AuMEGA Announces Oversubscribed Financing
|
18 Feb 2026 2:26PM |
$0.039 |
$0.038 |
fallen by
2.56%
|
|
AAM - Price-sensitive ASX Announcement
Full Release
Key Points
- AuMEGA Metals Ltd announces C$30 million upsized financing.
- Financing anchored by Condire Investors, LLC.
- B2Gold Corp. maintains 9.9% ownership.
- Proceeds to fund exploration in Newfoundland, Canada.
- Two-tranche structure with Tranche Two requiring shareholder approval.
- Premium Flow-Through component priced at a 36% premium.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bell Financial Group Limited (BFG) ORDINARY FULLY PAID |
Financials |
$411 |
Bell Financial Group 2025 Corporate Governance Statement
|
18 Feb 2026 2:26PM |
$1.300 |
$1.280 |
fallen by
1.54%
|
|
| Bell Financial Group Limited (BFG) ORDINARY FULLY PAID |
Financials |
$411 |
Bell Financial Group 2025 Appendix 4G
|
18 Feb 2026 2:24PM |
$1.300 |
$1.280 |
fallen by
1.54%
|
|
| Bell Financial Group Limited (BFG) ORDINARY FULLY PAID |
Financials |
$411 |
Dividend/Distribution - BFG
|
18 Feb 2026 2:23PM |
$1.300 |
$1.280 |
fallen by
1.54%
|
|
| Bell Financial Group Limited (BFG) ORDINARY FULLY PAID |
Financials |
$411 |
Bell Financial Group 2025 Appendix 4E and 2025 Annual Report
|
18 Feb 2026 2:23PM |
$1.300 |
$1.280 |
fallen by
1.54%
|
|
BFG - Price-sensitive ASX Announcement
Full Release
Key Points
- Bell Financial Group's revenue increased by 8.2% to $299.2 million in 2025.
- Net profit after tax rose by 17.1% to $36 million.
- Earnings per share grew by 17.7% to 11.3 cents.
- Total dividend per share increased to 9.5 cents, up by 18.8%.
- Funds under advice reached a record of $92.1 billion.
- The Bell Financial Trust reported a significant increase in client funds.
- The company has employed a comprehensive risk management framework addressing various business risks.
- Significant focus was placed on cybersecurity and information security.
- The company has a substantial presence in Australia and international markets, including offices in Hong Kong, New York, and London.
- The audit report confirmed a true and fair view of the financial position as of 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MA Credit Income Trust (MA1) ORDINARY UNITS FULLY PAID |
- |
$551 |
Daily Estimate NTA for 17.02.2026
|
18 Feb 2026 2:20PM |
$2.005 |
$1.970 |
fallen by
1.75%
|
|
| IGO Limited (IGO) ORDINARY FULLY PAID |
Materials |
$5,823 |
Appointment of Non-Executive Director
|
18 Feb 2026 2:18PM |
$8.160 |
$7.690 |
fallen by
5.76%
|
|
| Revolution Private Credit Income Trust (REV) ORDINARY UNITS FULLY PAID |
Financials |
$458 |
Weekly Estimate NTA for 17.02.2026
|
18 Feb 2026 2:18PM |
$2.020 |
$1.990 |
fallen by
1.49%
|
|
| Rhythm Biosciences Limited (RHY) ORDINARY FULLY PAID |
Health Care |
$69 |
Half-Year Financial Report and Appendix 4D
|
18 Feb 2026 2:14PM |
$0.220 |
$0.210 |
fallen by
4.55%
|
|
RHY - Price-sensitive ASX Announcement
Full Release
Key Points
- Rhythm Biosciences Limited reported a net loss of $2,257,186 for the half-year ending 31 December 2025.
- The company's cash outflows from operations were $3,798,670, reflecting continued investment in commercialization activities.
- ColoSTAT® achieved significant milestones, transitioning from development to active commercialization.
- Rhythm Biosciences completed a $3.75 million capital raising, reflecting strong investor confidence.
- The company's net assets increased to $2,143,433 from $659,892 as of 30 June 2025.
- The company recognized revenue of $1,652,334, primarily from research and development grants.
- Notable strategic partnerships and agreements were secured to expand the commercial and scientific reach of geneTypeâ„¢.
- The financial report includes a statement of material uncertainty regarding the company's ability to continue as a going concern.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gryphon Capital Income Trust (GCI) ORDINARY UNITS FULLY PAID |
Financials |
$1,278 |
Net Tangible Asset Backing
|
18 Feb 2026 2:12PM |
$2.070 |
$2.010 |
fallen by
2.90%
|
|
| Renegade Exploration Limited (RNX) ORDINARY FULLY PAID |
Materials |
$6 |
Investor Presentation - RIU Explorers Conference
|
18 Feb 2026 2:11PM |
$0.005 |
$0.003 |
fallen by
33.33%
|
|
| Kaili Resources Limited (KLR) 125C ORDINARY FULLY PAID |
Energy |
$19 |
REEs pXRF Drilling Results at Mallee Project SA
|
18 Feb 2026 2:09PM |
$0.155 |
$0.130 |
fallen by
16.13%
|
|
KLR - Price-sensitive ASX Announcement
Full Release
Key Points
- Kaili Resources Limited conducted an Aircore drilling program at the Mallee Project in South Australia.
- The drilling program focused on the Lameroo EL 6856 and Coodalya EL 6978 tenements.
- pXRF scans from the drilling program provided initial results for Total Rare Earth Elements (TREE).
- Significant pXRF drilling results included high TREE values in multiple holes.
- 52 samples exceeding 200ppm TREE have been sent to ALS laboratory for full suite REE analysis.
- The project area is located approximately 200 km east of Adelaide within the Murray Basin.
- The exploration focuses on ionic clay style REE deposits in the Loxton/Parilla Sands.
- Australian Rare Earths (AR3) reported success in nearby tenements, supporting the project's potential.
- The drilling program aimed to minimize disruptions by drilling along roadside verges with council approvals.
- Future exploration plans include up to 300 holes and 6,000 metres of drilling as per approvals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$126 |
Capital Structure Update
|
18 Feb 2026 2:08PM |
$0.620 |
$0.515 |
fallen by
16.94%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$126 |
Top 20 CDI Holder List
|
18 Feb 2026 2:05PM |
$0.620 |
$0.515 |
fallen by
16.94%
|
|
| Nick Scali Limited (NCK) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,364 |
Change of Director's Interest Notice - N Peiris
|
18 Feb 2026 2:03PM |
$19.130 |
$15.950 |
fallen by
16.62%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$126 |
Nyrada Half Year FY2026 Results
|
18 Feb 2026 2:02PM |
$0.620 |
$0.515 |
fallen by
16.94%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$126 |
Appendix 4D and Half Year Report to 31 December 2025
|
18 Feb 2026 1:58PM |
$0.650 |
$0.515 |
fallen by
20.77%
|
|
NYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Nyrada Inc reported a half-year loss of $3,187,188.
- The loss increased by 30% compared to the previous period.
- Research and development expenditure totaled $1,659,279.
- The company's lead candidate, Xolatryp®, is progressing to Phase II clinical trials.
- Xolatryp® targets TRPC ion channels and is aimed at treating ischemia reperfusion injury.
- Nyrada raised funds through the issuance of common stock.
- The report was signed on 18 February 2026 by Non-Executive Chair John Moore.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EBOS Group Limited (EBO) ORDINARY FULLY PAID |
Health Care |
$3,752 |
Application for quotation of securities - EBO
|
18 Feb 2026 1:57PM |
$20.860 |
$18.300 |
fallen by
12.27%
|
|
| Tarrina Resources Limited (TR8) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
Notification of cessation of securities - TR8
|
18 Feb 2026 1:56PM |
$0.029 |
$0.020 |
fallen by
31.03%
|
|
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$19 |
1H FY26 Results and Investor Webinar Notification
|
18 Feb 2026 1:51PM |
$0.125 |
$0.084 |
fallen by
32.80%
|
|
| SenSen Networks Limited (SNS) ORDINARY FULLY PAID |
Information Technology |
$41 |
FY25 R&D Tax Offset Refund Received
|
18 Feb 2026 1:44PM |
$0.047 |
$0.050 |
risen by
6.38%
|
|
| Qualitas Real Estate Income Fund (QRI) ORDINARY UNITS FULLY PAID |
Financials |
$997 |
Estimated Weekly NTA as at 16.02.2026
|
18 Feb 2026 1:43PM |
$1.590 |
$1.580 |
fallen by
0.63%
|
|